Buparlisib (BKM120)
别名: NVP-BKM120
中文名称:布帕尼西
目录号:S2247 Purity: 99.93%
Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂,在无细胞试验中作用于p110α/β/δ/γ的IC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34,mTOR,DNAPK 的作用效果下降,而对 PI4Kβ几乎没有活性。Buparlisib 可诱导凋亡。Phase 2。
CAS: 944396-07-0
客户使用Selleck的Buparlisib (BKM120)发表文献277篇
- Nat Neurosci, 2024 27(8):1555-1564.
- Mol Cancer, 2023 22(1):119
- Cancer Cell, 2022 S1535-6108(22)00005-8
- Cancer Discov, 2022 12(6):1542-1559
- Cancer Cell, 2021 S1535-6108(21)00284-1
- Cancer Discov, 2021 candisc.1265.2020
- Cell, 2020 S0092-8674(20)31394-5
- Cell, 2020 25;181(7):1596-1611.e27.
- Cancer Cell, 2020 37(2):183-199
- Nat Immunol, 2020 21(4):442-454
- Science, 2019 364(6441)
- Cancer Discov, 2019 9(9):1306-1323
- Nat Cell Biol, 2019 21(2):226-237
- J Thorac Oncol, 2019 14(6):1061-1076
- Cancer Cell, 2018 34(6):922-938
- Cancer Cell, 2018 33(1):91-107
- Nat Biomed Eng, 2018 2(8):578-588
- Nat Biomed Eng, 2018 2(4):239-253
- Cell, 2017 161(4):803-16
- Cancer Discov, 2017 7(9):1018-1029
- Cell Stem Cell, 2017 20(2):233-246
- Nature, 2016 529(7586):413-417
- J Hematol Oncol, 2016 9(1):113
- Cancer Discov, 2016 6(10):1134-1147
- Nat Cell Biol, 2016 18(12):1324-1335
- Blood, 2016 127(10):1325-35
- Nat Med, 2015 21(9):1038-47
- Nat Med, 2015 10.1038/nm.3855
- Cancer Discov, 2015 5(11):1194-209
- Cancer Discov, 2014 4(1):69-79
- Cancer Discov, 2013 4(2):232-45
- Cancer Discov, 2013 4(2):186-99
- Nat Med, 2012 18(6):892-901
- Cell, 2012 27;149(3):656-70.
- Cancer Cell, 2012 21(2):155-67
- Biomark Res, 2024 12(1):43
- Br J Cancer, 2024 131(9):1543-1554
- Cell Rep, 2024 43(10):114784
- Biomed Pharmacother, 2024 180:117569
- Cell Death Discov, 2024 10(1):175
- Cell Oncol (Dordr), 2024 10.1007/s13402-024-00939-5
- J Gastroenterol, 2024 10.1007/s00535-024-02192-x
- J Cell Mol Med, 2024 28(9):e18374
- Sci Rep, 2024 14(1):25526
- Mol Carcinog, 2024 10.1002/mc.23743
- PLoS Comput Biol, 2024 20(10):e1012488
- Toxicol In Vitro, 2024 97:105801
- bioRxiv, 2024 2024.04.28.591568
- Cancer Res Commun, 2024 4(4):1120-1134
- Adv Sci (Weinh), 2023 10(3):e2205529
- Cell Rep Med, 2023 10.1016/j.xcrm.2023.101285
- Blood Cancer J, 2023 13(1):42
- Proc Natl Acad Sci U S A, 2023 120(8):e2213272120
- Cell Rep, 2023 42(5):112529
- EMBO Rep, 2023 24(7):e56937
- J Transl Med, 2023 21(1):134
- Int J Mol Sci, 2023 24(2)1359
- Sci Adv, 2023 9(5):eade8641
- Res Sq, 2023 10.21203/rs.3.rs-3314138/v1
- UNIVERSITY OF APPLIED SCIENCES, 2023
- Nat Commun, 2022 13(1):2500
- Cell Rep Med, 2022 3(5):100623
- Clin Cancer Res, 2022 28-20:4444-4455
- Proc Natl Acad Sci U S A, 2022 119(43):e2203180119
- Pharmacol Res, 2022 179:106226
- Cell Rep, 2022 41(10):111759
- Phytomedicine, 2022 101:154116
- Elife, 2022 11e73796
- Breast Cancer Res, 2022 24(1):41
- Mol Oncol, 2022 10.1002/1878-0261.13217
- Mol Oncol, 2022 16(5):1091-1118
- iScience, 2022 25(10):105182
- Mol Cancer Ther, 2022 21(6):1020-1029
- Front Pharmacol, 2022 13:1049640
- Int J Mol Sci, 2022 23-1710132
- Int J Mol Sci, 2022 23(8)4295
- Cancers (Basel), 2022 14(3)673
- Cancers (Basel), 2022 14(18)4467
- Cancers (Basel), 2022 14(10)2397
- Cancers (Basel), 2022 14(6)1575
- J Biol Chem, 2022 S0021-9258(22)01309-6
- Oral Oncol, 2022 131:105939
- Sci Rep, 2022 12(1):5718
- Sci Rep, 2022 12(1):6345
- BMC Cancer, 2022 22(1):1193
- Mol Genet Genomic Med, 2022 e2106.
- J Neurol Surg B Skull Base, 2022 83(1):87-98
- Nat Commun, 2021 12(1):5053
- Nat Commun, 2021 12(1):3140
- Nat Commun, 2021 12(1):1920
- Mol Cell, 2021 S1097-2765(21)00232-X
- J Clin Invest, 2021 131(24)e140436
- Adv Sci (Weinh), 2021 e2103360
- Theranostics, 2021 11(8):3552-3564
- Clin Cancer Res, 2021 10.1158/1078-0432.CCR-21-1943
- Clin Cancer Res, 2021 10.1158/1078-0432.CCR-21-3359
- Cancer Res, 2021 canres.CAN-21-0164-A.2021
- Cell Death Dis, 2021 12(8):713
- Cell Death Dis, 2021 12(6):546
- Cell Death Dis, 2021 12(4):400
- Cell Death Dis, 2021 12(1):108
- iScience, 2021 24(9):102931
- Cancer Cell Int, 2021 21(1):24
- Front Cell Infect Microbiol, 2021 11:734750
- Oncotarget, 2021 12(7):674-685
- Bioorg Chem, 2021 117:105405
- Front Oncol, 2021 11:782065
- Cell Biol Int, 2021 10.1002/cbin.11557
- Genome Med, 2020 18;12(1):17
- Br J Cancer, 2020 10.1038/s41416-020-01074-2
- Cell Rep, 2020 33(1):108221
- Cell Rep, 2020 31(12):107800
- Sci Signal, 2020 3;13(621) pii: eaax2364
- Mol Oncol, 2020 10.1002/1878-0261.12673
- Cancer, 2020 10.1002/cncr.33071
- Commun Biol, 2020 3(1):593
- NPJ Breast Cancer, 2020 6:30
- Am J Cancer Res, 2020 10(12):4488-4497
- Am J Cancer Res, 2020 10(11):3765-3783
- Cancers (Basel), 2020 12(9)E2500
- Mol Cancer Res, 2020 11
- Eur J Pharmacol, 2020 870:172821
- Sci Rep, 2020 10(1):16208
- Front Neurosci, 2020 2;14:223
- Cell Biol Int, 2020 10.1002/cbin.11322
- BMC Cancer, 2020 20(1):724
- Turk J Haematol, 2020 37(3):167-176
- Genes Cancer, 2020 11(3-4):106-121
- FASEB Bioadv, 2020 2(2):126-144
- Small GTPases, 2020 10.1080/21541248
- Nat Commun, 2019 10(1):1515
- Nat Commun, 2019 10(1):259
- Nat Commun, 2019 10(1):2910
- Cell Death Differ, 2019 10.1038/s41418-019-0422-6
- Theranostics, 2019 9(8):2380-2394
- Leukemia, 2019 10.1038/s41375-019-0556-z
- Cancer Lett, 2019 466:23-34
- Cell Syst, 2019 8(2):97-108
- Cell Rep, 2019 28(9):2317-2330
- Cell Rep, 2019 27(2):631-647
- Cell Rep, 2019 27(1):294-306
- NPJ Breast Cancer, 2019 05:31
- Mol Cancer Ther, 2019 18(4):834-844
- Mol Ther Oncolytics, 2019 13:58-66
- J Cell Physiol, 2019 234(7):10907-10917
- Eur J Immunol, 2019 doi: 101002/eji201948241
- Am J Cancer Res, 2019 9(12):2774-2788
- Cancers (Basel), 2019 11(1)E37
- Cancers (Basel), 2019 11(2)
- Aging (Albany NY), 2019 11(18):7780-7795
- Chem Biol Interact, 2019 302:101-107
- Eur J Pharmacol, 2019 842:89-98
- Front Oncol, 2019 9:1119
- Front Oncol, 2019 0.87569444444
- Biochem J, 2019 476(23):3583-3593
- Mol Pharmacol, 2019 95(5):528-536
- Biochem Biophys Res Commun, 2019 513(3):546-552
- Oncol Lett, 2019 18(6):6249-6260
- Oncol Lett, 2019 17(3-:3151-3162
- Prostate, 2019 79(11):1347-1359
- Leuk Lymphoma, 2019 10.1080/10428194.2019.1594211
- Int J Hematol, 2019 110(2):213-227
- Nat Commun, 2018 9(1):1357
- Nat Commun, 2018 9(1):4550
- J Exp Med, 2018 215(1):159-175
- Nat Protoc, 2018 13(12):2827-2843
- Cancer Res, 2018 78(14):4007-4021
- Cancer Res, 2018 78(8):2000-2013
- Cancer Res, 2018 78(9):2383-2395
- EMBO Mol Med, 2018 10(5)
- Cancer Lett, 2018 439:56-65
- Cell Rep, 2018 24(2):463-478
- Cell Rep, 2018 24(8):2155-2166
- Oncogene, 2018 37(3):363-376
- Elife, 2018 7e33718
- Sci Signal, 2018
- Int J Cancer, 2018 142(9):1926-1937
- Int J Cancer, 2018 143(5):1188-1201
- NPJ Breast Cancer, 2018 4:36
- Mol Cancer Ther, 2018 17(7):1526-1539
- Mol Cancer Ther, 2018 17(9):2049-2059
- Mol Cancer Ther, 2018 17(2):347-354
- Oncotarget, 2018 9(56):30869-30882
- NPJ Genom Med, 2018 3:15
- Mol Cancer Res, 2018 16(4):599-609
- Sci Rep, 2018 8(1):10784
- Oncol Rep, 2018 40(6):3223-3234
- Oncol Rep, 2018 40(1):479-487
- PLoS One, 2018 13(2):e0191890
- Oncol Lett, 2018 15(3):3321-3328
- Nat Commun, 2017 8;8:15617
- Nat Commun, 2017 8:15623
- Nat Commun, 2017 8(1):1278
- Nat Commun, 2017 8:15021
- Mol Cell, 2017 65(6):999-1013
- Mol Cell, 2017 67(3):512-527
- Dev Cell, 2017 43(6):673-688
- Clin Cancer Res, 2017 23(11):2795-2805
- Cancer Res, 2017 77(16):4448-4459
- Proc Natl Acad Sci U S A, 2017 114(41):E8628-E8636
- Breast Cancer Res, 2017 19(1):105
- Mol Cell Proteomics, 2017 16(10):1864-1888
- Mol Cancer Ther, 2017 16(9):1779-1790
- Mol Cancer Ther, 2017 16(4):729-738
- Mol Cancer Ther, 2017 10.1158/1535-7163
- Oncotarget, 2017 8(5):7878-7890
- Oncotarget, 2017 8(44):76935-76948
- Oncotarget, 2017 8(32):52474-52487
- Oncotarget, 2017
- Oncotarget, 2017
- Oncotarget, 2017 8(4):6608-6622
- Oncotarget, 2017 8(13):21806-21817
- BMC Cancer, 2017
- SLAS Discov, 2017 22(8):974-984
- Genome Biol, 2016 17:80
- Clin Cancer Res, 2016 22(3):644-56.
- Cancer Res, 2016 76(24):7168-7180
- PLoS Biol, 2016 14(11):e1002581
- Cell Rep, 2016
- J Transl Med, 2016 14:56
- Oncotarget, 2016 7(29):45414-45428
- Oncotarget, 2016
- Oncotarget, 2016 7(45):72608-72621
- Oncotarget, 2016 7(26):40398-40417
- Oncotarget, 2016 7(41):67277-67287
- Sci Rep, 2016 6:20189
- Int J Biochem Cell Biol, 2016 79:308-317
- PLoS One, 2016 11(1):e0147682
- PLoS One, 2016 10.1371/journal
- J Clin Invest, 2015 125(12):4559-71
- J Clin Invest, 2015 10.1172/JCI78018
- Cancer Res, 2015 75(14):2851-62
- Proc Natl Acad Sci U S A, 2015 112(28):8638-43
- Genes Dev, 2015 29(16):1677-82
- Acta Pharmacol Sin, 2015 10.1038/aps.2015.4
- Oncogene, 2015 10.1038/onc.2015.173
- Biomed Pharmacother, 2015 75:40-50
- Glia, 2015 63(10):1850-9
- Crit Rev Oncol Hematol, 2015
- Int Immunopharmacol, 2015 28(1):675-85
- Oncotarget, 2015 6(12):10399-414
- Oncotarget, 2015 6(31):31792-804
- Cell Signal, 2015 27(12):2389-400
- Gynecol Oncol, 2015 138(1):165-73
- Immunol Res, 2015 10.1007/s12026-015-8648-y
- Int J Biochem Cell Biol, 2015 60C:34-42
- PLoS One, 2015 10(9):e0133610
- PLoS One, 2015 10(4):e0123410
- Exp Cell Res, 2015 332(2):223-35
- J Clin Invest, 2014 124(12):5490-502
- J Clin Invest, 2014 124(11):4737-52
- J Exp Med, 2014 211(13):2497-2505
- Cancer Res, 2014 10.1158/0008-5472.CAN-14-1392
- Cell Death Dis, 2014 5:e1013
- Cell Death Dis, 2014 5:e1134
- Cell Rep, 2014 8(5):1265-70
- Oncogene, 2014 10.1038/onc.2014.328
- Breast Cancer Res, 2014 16(4):406
- Breast Cancer Res, 2014 16(1):R9
- PLoS Pathog, 2014 10(6):e1004196
- Oncotarget, 2014 5(14):5295-303
- Mol Cancer Res, 2014 12(10):1520-31
- J Biol Chem, 2014 289(33):22785-97
- Epigenetics, 2014 9(4):611-20
- PLoS One, 2014 9(10):e108780
- PLoS One, 2014 9(7):e101969
- Biochem Biophys Res Commun, 2014 10.1016/j.bbrc.2014.09.129
- Assay Drug Dev Technol, 2014 12(9-10):514-26
- Clin Cancer Res, 2013 19(21):5940-51
- Cancer Res, 2013 73(17):5459-72
- Cell Commun Signal, 2013 11(1):3
- Oncogene, 2013 10.1038/onc.2013.509
- Breast Cancer Res, 2013 15(4):R55
- Mol Cancer Res, 2013 11(10):1269-78
- BMC Cancer, 2013 13:465
- Cancer Chemother Pharmacol, 2013 71(5):1297-307
- University Gattingen, 2013 Elisabeth Hand
化学信息&溶解度
分子量 | 410.39 |
分子式 | C18H21F3N6O2 |
CAS号 | 944396-07-0 |
Smiles | C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4 |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 82 mg/mL ( 199.8 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 82 mg/mL Water : Insoluble DMSO : 82 mg/mL ( 199.8 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 16 mg/mL Water : Insoluble DMSO : 82 mg/mL ( 199.8 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 52 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:4.1mg/ml
(9.99mM)
操作示例:以 1 mL 工作液为例,取50μL82mg/ml的澄清DMSO储备液加到400μLPEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μLddH2O定容至1mL。工作液请现配现用!
|
|
5% DMSO
95% Corn oil
浓度:0.3mg/ml
(0.73mM)
操作示例:以1 mL工作液为例,取50μL 6mg/ml的澄清DMSO储备液加到950μL玉米油中,混合均匀。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。